Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study

BACKGROUND: Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial fibrillation (NVAF). However, the safety and effectiveness of apixaban in clinical practice have not yet been elucidated thor...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Hiroshi, Umeyama, Michiaki, Yamada, Takako, Hashimoto, Hiroyuki, Komoto, Akira, Yasaka, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595349/
https://www.ncbi.nlm.nih.gov/pubmed/31293700
http://dx.doi.org/10.1002/joa3.12184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595349/
https://www.ncbi.nlm.nih.gov/pubmed/31293700
http://dx.doi.org/10.1002/joa3.12184

Ejemplares similares